Home › Castration-Resistant Prostatic Cancer › North Carolina
Castration-Resistant Prostatic Cancer clinical trials in North Carolina
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in North Carolina.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Duke University Medical Center, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Levine Cancer Institute, Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
- W.G. Bill Hefner VA Medical Center, Salisbury
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 18 and older · Men · Updated Apr 13, 2026 · NCT04337580From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.